Preliminary clinical observation of concurrent radiochemotherapy for 31 patients with stage Ⅱ nasal cavity natural killer/T cell lymphoma
10.3760/cma.j.issn.1009-9921.2015.08.008
- VernacularTitle:同期放化疗治疗Ⅱ期鼻腔NK/T细胞淋巴瘤31例初步临床效果观察
- Author:
Lu HUANG
;
Yunhong HUANG
;
Tao WU
;
Yunfei HU
;
Ling DING
;
Yajun MIAO
;
Yongling WANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,extranodal NK-T-cell;
Concurrent radiochemotherapy;
Radiotherapy,intensity-modulated;
Drug toxicity;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2015;24(8):475-478,482
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the primary clinical effect of concurrent radiochemotherapy for patients with nasal cavity natural killer (NK)/T cell lymphoma and to analyze the prognostic factors.Methods 31 primary untreated patients with stage Ⅱ nasal cavity NK/T cell lymphoma were enrolled for this study.All patients underwent concurrent radiochemotherapy with intensity-modulated radiotherapy technique + asparaginase based chemotherapeutic agents and adjuvant chemotherapy.Results The main toxicities were mouth mucocitis,myelosuppression and xerosmia at grade 1 or 2.31 patients achieved good clinical shortterm effect with high local complete remission rate at the 3rd month after radiotherapy [83.9 ％ (26/31)],and the 2-year overall survival rate was 77 ％.Univariate and multivariate analysis suggested IPI score and clinical short-term effect were the significant independent survival prognostic factors (P ＜ 0.05).Conclusions Concurrent radiochemotherapy for stage Ⅱ nasal cavity NK/T cell lymphoma can be well tolerated by patients with mild toxicities,and can improve both clinical short-term effect and overall survival by high local complete remission rate.IPI score and clinical short-term effect are the important survival prognostic factors.
